Skip to contentA
Anika Therapeutics, Inc.
A
ANIKAnika Therapeutics, Inc. Q2 2016 · 10-Q
Revenue$26.58M$26.58M+16.1% vs Q2 2015 Net Income$8.62M$8.62M+10.2% vs Q2 2015 EPS Diluted$0.57$0.57+11.8% vs Q2 2015 Gross Profit$20,510,000+16.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anika Therapeutics, Inc. · CIK 898437 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,037,000N/M Free Cash Flowderived-$4,488,000N/M Margins · derivedGross margin77.2%+0.2 pt vs Q2 2015
Operating margin50.7%−3.6 pt vs Q2 2015
Net margin32.4%−1.7 pt vs Q2 2015
ended Jun 30, 2016 · filed Aug 1, 2016 · 32 d after period end